For the week ending January 10, Alternatives Watch has tracked more than $1.8 billion in private financing deals done by private equity firms, institutional investors and hedge funds in the life sciences arena.
Some of the more well-known investors this past week include Tiger Global Management, Mirae Asset, New Enterprise Associates, Blackrock, Viking Global, Citadel's Surveyor Capital and others. All told these investors are supporting research in infectious disease, digital health and gene-based cancer therapy expansion.
The deals outlined are all of the financing rounds totaling $40 . . .
Continue Reading
Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.
Monthly
$30
A pay-as-you-go plan to get you started
→ Instantly unlock all new and archived articles
→ Daily, weekly and monthly e-mail newsletters
→ Access to the weekly AW Deal Watch by AW Research
Annual
$300
Get more for less - 20% discount over monthly
→ Everything in Monthly PLUS:
→ Access to articles and data from AW Research
→ AW Annual Investor Compendium – our comprehensive guide to investor activity, with a ranking of the most active investors for the year and profiles of the top global allocators
